ARIKAYCE (amikacin liposome inhalation suspension)

ARIKAYCE (amikacin liposome inhalation suspension) is the first and only therapy specifically indicated for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

www.arikayce.com